01. Doctor Overview

Doctor Overview

Dr. Suresh S. Ramalingam is a thoracic oncologist and deputy director at Winship Cancer Institute of Emory University in Atlanta, Georgia. He is board certified in internal medicine and medical oncology. Prior to joining Winship Cancer Institute, Dr. Ramalingam completed a residency in internal medicine at Wayne State University, as well as a fellowship in hematology and medical oncology at the University of Pittsburgh Cancer Institute.

Dr. Ramalingam serves as an investigator and physician, specializing in small cell and non-small cell lung cancer. He has authored more than 200 publications, and also serves as a section editor for “Chest Diseases” in Cancer. In his clinical trial research, Dr. Ramalingam explores the development of immune checkpoint inhibitors for small cell and non-small cell lung cancer. He also researches immunotherapy and potential outcomes for patients with an EGFR mutation, which causes lung cancer.

02. Fast Facts

Doctor Fast Facts

Main Specialty: Thoracic Oncology

Other Interests & Specialties: Hematology, immunotherapy, non-small cell lung cancer, small cell lung cancer and targeted therapy.

Certifications, Awards & Accolades: Georgia Cancer Coalition Distinguished Cancer Scholar, President of the Georgia Society of Oncology, James Eckman Award for Excellence in Teaching at Emory, ECOG-ACRIN Young Investigator Award, NCI Cancer Clinical Investigator Team Leadership Award, Atlanta’s Top Doctors by Atlanta Magazine in 2018, member of MilliPub Club at Emory University School of Medicine

Education & Experience:

  • Medical Degree from Kilpauk Medical College at the University of Madras in Madras, India
  • Residency in Internal Medicine at Wayne State University
  • Fellowship in Hematology and Medical Oncology at the University of Pittsburgh Cancer Institute
03. Publications


Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine. November 2019;381(21):2020-2031. doi: 10.1056/NEJMoa1910231

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. Journal of Thoracic Oncology. January 2009;4(1):97-101. doi: 10.1097/JTO.0b013e318191520c

Recent advances in the treatment of malignant pleural mesothelioma. Journal of Thoracic Oncology. September 2008;3(9):1056-64. doi: 10.1097/JTO.0b013e3181834f66